<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001221620
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Lepica
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PREGABALIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        75
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Controlled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        51.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Laboratorios Liconsa S.A" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Laboratorios Liconsa S.A
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Medical Valley Invest AB 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N03AX16
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>LEPICA belongs to a group of medicines used to treat epilepsy, neuropathic pain and Generalised Anxiety Disorder (GAD) in adults.</p><p><strong>Peripheral and central neuropathic pain: </strong>LEPICA is used to treat long lasting pain caused by damage to the nerves. A variety of diseases can cause peripheral neuropathic pain, such as diabetes or shingles. Pain sensations may be described as hot, burning, throbbing, shooting, stabbing, sharp, cramping, aching, tingling, numbness, pins and needles. Peripheral and central neuropathic pain may also be associated with mood changes, sleep disturbance, fatigue (tiredness), and can have an impact on physical and social functioning and overall quality of life.</p><p><strong>Epilepsy: </strong>LEPICA is used to treat a certain form of epilepsy (partial seizures with or without secondary generalisation) in adults. Your doctor will prescribe LEPICA for you to help treat your epilepsy when your current treatment is not controlling your condition. You should take LEPICA in addition to your current treatment. LEPICA is not intended to be used alone, but should always be used in combination with other anti-epileptic treatment.</p><p><strong>Generalised Anxiety Disorder: </strong>LEPICA is used to treat Generalised Anxiety Disorder (GAD). The symptoms of GAD are prolonged excessive anxiety and worry that are difficult to control. GAD can also cause restlessness or feeling keyed up or on edge, being easily fatigued (tired), having difficulty</p><p>concentrating or mind going blank, feeling irritable, having muscle tension or sleep disturbance. This is different to the stresses and strains of everyday life.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take LEPICA</strong></p><p>If you are allergic to pregabalin or any of the other ingredients of this medicine (listed in section 6).</p><p><strong>Warnings and Precautions</strong></p><ul><li>Some patients taking LEPICA have reported symptoms suggesting an allergic reaction. These symptoms include swelling of the face, lips, tongue, and throat, as well as diffuse skin rash. Should you experience any of these reactions, you should contact your physician immediately.</li><li>LEPICA has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in elderly patients. Therefore, you should be careful until you are used to any effect the medicine might have.</li><li>LEPICA may cause blurring or loss of vision, or other changes in eyesight, many of which are temporary. You should immediately tell your doctor if you experience any changes in your vision.</li><li>Some patients with diabetes who gain weight while taking pregabalin may need an alteration in their diabetic medicines.</li><li>Certain side effects may be more common, such as sleepiness, because patients with spinal cord injury may be taking other medicines to treat, for example, pain or spasticity, that have similar side effects to Pregabalin and the severity of these effects may be increased when taken together.</li><li>&nbsp;There have been reports of heart failure in some patients when taking LEPICA; these patients were mostly elderly with cardiovascular conditions. <strong>Before taking this medicine, you should tell your doctor if you have a history of heart disease</strong>.</li><li>There have been reports of kidney failure in some patients when taking LEPICA. If while taking LEPICA you notice decreased urination, you should tell your doctor as stopping the medicine may improve this.</li><li>A small number of people being treated with anti-epileptics such as LEPICA have had thoughts of harming or killing themselves. If at any time you have these thoughts, immediately contact your doctor.</li><li>When LEPICA is taken with other medicines that may cause constipation (such as some types of pain medicines) it is possible that gastrointestinal problems may occur (e.g., constipation, blocked or paralysed bowel). Tell your doctor if you experience constipation, especially if you are prone to this problem.</li><li>Before taking this medicine you should tell your doctor if you have a history of alcoholism or any drug abuse or dependence. Do not take more medicine than prescribed.</li><li>There have been reports of convulsions when taking LEPICA or shortly after stopping LEPICA. If you experience a convulsion, contact your doctor immediately.</li><li>There have been reports of reduction in brain function (encephalopathy) in some patients taking LEPICA when they have other conditions. Tell your doctor if you have a history of any serious medical conditions, including liver or kidney disease.</li></ul><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>The safety and efficacy in children and adolescents (under 18 years of age) has not been established and therefore, pregabalin should not be used in this age group.</p><p>&nbsp;</p><p><strong>Other medicines and LEPICA</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>LEPICA and certain other medicines may influence each other (interaction). When taken with certain other medicines, LEPICA may potentiate the side effects seen with these medicines, including respiratory failure and coma. The degree of dizziness, sleepiness and decreased concentration may be increased if LEPICA is taken together with medicinal products containing:</p><p>&nbsp;</p><p>Oxycodone &ndash; (used as a pain-killer) Lorazepam &ndash; (used for treating anxiety) Alcohol</p><p>&nbsp;</p><p>LEPICA may be taken with oral contraceptives.</p><p>&nbsp;</p><p><strong>LEPICA with food, drink and alcohol</strong></p><p>LEPICA capsules may be taken with or without food. It is advised not to drink alcohol while taking LEPICA.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>LEPICA should not be taken during pregnancy, unless you are told otherwise by your doctor. Effective contraception must be used by women of child-bearing potential. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Driving and using machines</strong></p><p>LEPICA may produce dizziness, sleepiness and decreased concentration. You should not drive, operate complex machinery or engage in other potentially hazardous activities until you know whether this medicine affects your ability to perform these activities.</p><p><strong>LEPICA contains lactose monohydrate</strong></p><p>If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Your doctor will determine what dose is appropriate for you. LEPICA is for oral use only.</p><p><strong>Peripheral and central neuropathic pain, epilepsy or Generalised Anxiety Disorder:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take the number of capsules as instructed by your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The dose, which has been adjusted for you and your condition, will generally be between 150 mg and 600 mg each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will tell you to take LEPICA either twice or three times a day. For twice a day take LEPICA once in the morning and once in the evening, at about the same time each day. For three times a day take LEPICA once in the morning, once in the afternoon and once in the evening, at about the same time each day.</p><p>If you have the impression that the effect of LEPICA is too strong or too weak, talk to your doctor or pharmacist.</p><p>If you are an elderly patient (over 65 years of age), you should take LEPICA normally except if you have problems with your kidneys.</p><p>Your doctor may prescribe a different dosing schedule and/or dose if you have problems with your kidneys.</p><p>Swallow the capsule whole with water.</p><p>Continue taking LEPICA until your doctor tells you to stop.</p><p><strong>If you take more LEPICA than you should</strong></p><p>Call your doctor or go to the nearest hospital emergency unit immediately. Take your box or bottle of LEPICA capsules with you. You may feel sleepy, confused, agitated, or restless as a result of taking more LEPICA than you should.</p><p><strong>If you forget to take LEPICA</strong></p><p>It is important to take your LEPICA capsules regularly at the same time each day. If you forget to take a dose, take it as soon as you remember unless it is time for your next dose. In that case, just carry on with the next dose as normal. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking LEPICA</strong></p><p>Do not stop taking LEPICA unless your doctor tells you to. If your treatment is stopped it should be done gradually over a minimum of 1 week.</p><p>After stopping long and short-term LEPICA treatment, you need to know that you may experience certain side effects. These include, trouble sleeping, headache, nausea, feeling anxious, diarrhoea, flulike symptoms, convulsions, nervousness, depression, pain, sweating, and dizziness. These symptoms may occur more commonly or severely if you have been taking LEPICA for a longer period of time.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Very common: may affect more than 1 in 10 people:</strong></p><ul><li>Dizziness, drowsiness, headache</li></ul><p><strong>Common: may affect up to 1 in 10 people:</strong></p><ul><li>Increased appetite</li><li>Feeling of elation, confusion, disorientation, decrease in sexual interest, irritability</li><li>Disturbance in attention, clumsiness, memory impairment, loss of memory, tremor, difficulty with speaking, tingling feeling, numbness, sedation, lethargy, insomnia, fatigue, feeling abnormal</li><li>Blurred vision, double vision</li><li>Vertigo, problems with balance, fall</li><li>Dry mouth, constipation, vomiting, flatulence, diarrhoea, nausea, swollen abdomen</li><li>Difficulties with erection</li><li>Swelling of the body including extremities</li><li>Feeling drunk, abnormal style of walking</li><li>Weight gain</li><li>Muscle cramp, joint pain, back pain, pain in limb</li><li>Sore throat</li></ul><p><strong>Uncommon: may affect up to 1 in 100 people:</strong></p><ul><li>Loss of appetite, weight loss, low blood sugar, high blood sugar.</li><li>Change in perception of self, restlessness, depression, agitation, mood swings, difficulty finding words, hallucinations, abnormal dreams, panic attack, apathy, aggression, elevated mood, mental impairment, difficulty with thinking, increase in sexual interest, problems with sexual functioning including inability to achieve a sexual climax, delayed ejaculation.</li><li>Changes in eyesight, unusual eye movement, changes in vision including tunnel vision, flashes of light, jerky movements, reduced reflexes, increased activity, dizziness on standing, sensitive skin, loss of taste, burning sensation, tremor on movement, decreased consciousness, loss of consciousness, fainting, increased sensitivity to noise, feeling unwell.</li><li><p>Dry eyes, eye swelling, eye pain, weak eyes, watery eyes, eye irritation.</p></li><li><p>Heart rhythm disturbances, increased heart rate, low blood pressure, high blood pressure, changes in heart beat, heart failure.</p></li><li><p>Flushing, hot flushes.</p></li><li><p>Difficulty breathing, dry nose, nasal congestion.</p></li><li><p>&nbsp;Increased saliva production, heartburn, numb around mouth.</p></li><li><p>Sweating, rash, chills, fever.</p></li><li><p>Muscle twitching, joint swelling, muscle stiffness, pain including muscle pain, neck pain.</p></li><li><p>Breast pain.</p></li><li><p>Difficulty with or painful urination, incontinence.</p></li><li><p>&nbsp;Weakness, thirst, chest tightness.</p></li><li><p>Changes in blood and liver test results (blood creatinine phosphokinase increased, alanine amino transferase increased, aspartate aminotransferase increased, platelet count decreased, neutropenia, increase in blood creatinine, decrease in blood potassium).</p></li><li><p>Hypersensitivity, swollen face, itchiness, hives, runny nose, nose bleed, cough, snoring. Painful menstrual periods.</p></li><li><p>Coldness of hands and feet.</p></li></ul><p>&nbsp;</p><p><strong>Rare: may affect up to 1 in 1,000 people:</strong></p><ul><li>Abnormal sense of smell, swinging vision, altered perception of depth, visual brightness, vision loss.</li><li>Dilated pupils, cross eyes.</li><li>Cold sweat, tightness of the throat, swollen tongue.</li><li>Inflammation of the pancreas.</li><li>Difficulty in swallowing.</li><li>Slow or reduced movement of the body.</li><li>Difficulty with writing properly.</li><li>Increased fluid in the abdomen.</li><li>Fluid in the lungs</li><li>Convulsions</li><li>Changes in the recording of electrical changes (ECG) in the heart which correspond to heart rhythm disturbances.</li><li>Muscle damage.</li><li>Breast discharge, abnormal breast growth, breast growth in males.</li><li>Interrupted menstrual periods.</li><li>Kidney failure, reduced urine volume, urinary retention.</li><li>Decrease in white blood cell count.</li><li>Inappropriate behaviour.</li><li>Allergic reactions (which may include difficulty breathing, inflammation of the eyes (keratitis) and a serious skin reaction characterized by rash, blisters, peeling skin and pain). Jaundice (yellowing of the skin and eyes).</li></ul><p><strong>Very rare: may affect up to 1 in 10.000 people</strong></p><ul><li>Liver failure.</li><li>Hepatitis (inflammation of the liver).</li></ul><p><strong>If you experience swollen face or tongue or if your skin turns red and starts to blister or peel, you should seek immediate medical advice.</strong></p><p>Certain side effects may be more common, such as sleepiness, because patients with spinal cord injury may be taking other medicines to treat, for example, pain or spasticity, that have similar side effects to Pregabalin and the severity of these effects may be increased when taken together.</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not store above 30 &ordm;C.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton or bottle after EXP. The expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is pregabalin. Each hard capsule contains either 25 mg<strong>, </strong>50 mg, 75 mg, 100 mg, 150 mg, 200 mg or 300 mg pregabalin.</p><p>The other ingredients are: lactose monohydrate, maize starch, talc, gelatin and titanium dioxide (E171).</p><p>50 mg and 200 mg capsules also contain red iron oxide (E172).</p><p>75 mg, 100 mg and 300 mg capsules also contain indigo carmine (E132) and erythrosine (E171)</p><p>LEPICA is available in Aluminium/Aluminium-Polyamide-PVC or Aluminium/PVC-PVDC blisters. LEPICA 75 mg contains 14, 56, 70, 100, 112 hard capsules or 100 x 1 hard capsules in perforated unit dose blisters</p><p>&nbsp;</p><p>LEPICA 150 mg contains 14, 56, 70, 100, 112 hard capsules or 100 x 1 hard capsules in perforated unit dose blisters</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What LEPICA looks like and contents of the pack
75 mg capsules	White and maroon hard capsules with approximate size of 14 mm.
150 mg capsules	White hard capsules with approximate size of 18 mm.

LEPICA is available in Aluminium/Aluminium-Polyamide-PVC or Aluminium/PVC-PVDC blisters. LEPICA 75 mg contains 14, 56, 70, 100, 112 hard capsules or 100 x 1 hard capsules in perforated unit dose blisters
LEPICA 150 mg contains 14, 56, 70, 100, 112 hard capsules or 100 x 1 hard capsules in perforated unit dose blisters

Not all pack sizes may be marketed.

To reports any side effect(s):
Saudi Arabia:
•	The National Pharmacovigilance Centre (NPC):
	SFDA Call Center: 19999
	E-mail: npc.drug@sfda.gov.sa 
	Website: https://ade.sfda.gov.sa/

Other GCC States:
	Please contact the relevant competent authority.



            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Medical Valley Invest AB,</p><p>Bradgardsvagen 28</p><p>236 32 Hollviken Sweden</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Laboratorios Liconsa S.A.,</p><p>Avda. Miralcampo, N&ordm;7, PI Miralcampo,</p><p>19200- Azuqueca de Henares - Guadalajara, Spain.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 May 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي لبيكا إلى مجموعة من الأدوية المستخدمة في عالج الصرع، وألم الاعتلال العصبي واضطراب القلق الـعـام (GAD) لدى البالغين.</p><p dir="RTL"><strong>ألــم الاعتلال العصبي الطرفي والمركزي</strong>: يستخدم لبيكا لعالج الألم طويل الأمد الناجم عن الأضرار التي لحقت بالأعصاب. وهناك مجموعة متنوعة من الأمراض قد تسبب آلام الأعصاب الطرفية، مثل مرض السكري أو داء القوباء المنطقية. ويمكن وصف احساس الألم بالسخونة، والحرقان، والخفقان، والحقن، والطعن، والجرح، والتشنج، والوجع، والتنميل، والخدر، والوخز بالدبابيس والإبر. ويمكن أيضاً أن ترتبط آلام الأعصاب الطرفية والمركزية مع تغيرات في المزاج، واضطراب النوم والإرهاق (التعب)، ويمكن أن يكون لها تأثير على الأداء الطبيعي والاجتماعي ونوعية الحياة عموماً.</p><p dir="RTL"><strong>الـصـرع</strong>: يستخدم لبيكا لعالج شكل معين من الصرع (النوبات الجزئية مع أو بدون تعميم ثانوي) لدى البالغين. سيقوم بطبيبك بوصف لبيكا لمساعدتك على علاج الصرع لديك عندما يكون علاجك الحالي لا يسيطر على حالتك. لبيكا غير مخصص للاستخدام وحده، بل يجب عليك دائماً استخدامه إلى جانب غيره من العلاجات المضادة للصرع.</p><p><strong>اضراب القلق العام: </strong>يستخدم لبيكا لعلاج اضطراب القلق العام (GAD). تتمثل أعراض اضراب القلق العام في القلق المفرط لفترات طويلة والقلق الذي يصعب السيطرة عليه. كما أن اضراب القلق العام يمكن أن يسبب للمريض الأرق أو الشعور بأنه في مكان مرتفع أو على حافة هاوية، أو الإرهاق بسهولة (التعب)، أو وجود&nbsp;صعوبة في التركيز أو أن العقول أصبح فارغاً أو الشعور السريع بالانفعال، مع التوتر العضلي أو اضطراب النوم. وهذا يختلف عن الضغوط وتوترات الحياة اليومية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول لبيكا</strong></p><p dir="RTL">إذا كان لديك حساسية من البريجابالين أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أبلغ بعض المرضى الذين يتناولون لبيكا عن أعراض تدل على رد الفعل التحسسي. وتشمل هذه الأعراض تورم الوجه والشفتان واللسان، والحلق، وكذلك طفح جلدي منتشر. إذا واجهت أي من ردود الفعل هذه، يجب عليك الاتصال بطبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتبط لبيكا مع الدوخــة والنعاس، والتي يمكن أن تزيد من حـدوث إصابة عرضية (الوقوع) لدى المرضى المسنين. لذلك، يجب توخي الحذر حتى الاعتياد على أي تأثير لهذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يسبب لبيكا عدم وضوح أو فقدان الرؤية، أو تغييرات أخرى في البصر، كثير منها مؤقتة. فعليك أن تخبر طبيبك فوراً إذا واجهت أي تغييرات في الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يحتاج بعض المرضى، الذين يعانون من مرض السكري الذين حصل لديهم زيادة بالوزن أثناء تناول بريجابالين، إلى تغيير في أدويتهم لعالج مرض السكري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تكون بعض التأثيرات الجانبية أكثر شيوعاً، مثل النعاس، لأن المرضى الذين يعانون من إصابات في النخاع الشوكي قد يأخذون أدوية أخرى لعلاج، على سبيل المثال، الآلام أو التشنجات، والتي يكون لها تأثيرات جانبية مشابهة لبريجابالين، عندئذ يمكن أن تزاد حدة هذه التأثيرات عندما تؤخذ معاً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هناك تقارير تتحدث عن حدوث فشل القلب لدى بعض المرضى عند تناول لبيكا. هؤلاء المرضى كانوا في الغالب كبار في السن ولديهم حالات بالقلب والأوعية الدموية. <strong>قبل تناول هذا الدواء. يجب إخبار الطبيب إذا كان لديك أي تاريخ من أمراض القلب</strong>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هناك تقارير تشير إلى إصابة بعض المرضى بفضل كلوي عند تناول لبيكا. إذا لاحظت خلال فترة تناول لبيكا تناقص في التبول، يجب عليك أن تخبر طبيبك فإن التوقف عن تناول هذا الدواء قد يحسن ذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القليل من الأشخاص الذين يتناولون علاجاً للصرع مثل لبيكا وأصبح لديهم أفكار لإيذاء أو قتل أنفسهم. إذا كان لديك في أي وقت مثل هذه الأفكار، اتصل بطبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند تناول لبيكا إلى جانب الأدوية الأخرى التي قد تسبب الإمساك (مثل بعض أنواع أدوية الألم)، من المحتمل أن تحدث مشاكل في الجهاز الهضمي (على سبيل المثال، الإمساك وانسداد أو شلل الأمعاء). أخبر طبيبك إذا عانيت من الإمساك، وبشكل خاص إذا كنت عرضة لهذه المشكلة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قبل تناول هذا الدواء يجب عليك إخبار طبيبك إذا كان لديك تاريخ من إدمان الكحول أو تعاطي المخدرات أو أي اعتماد على أدوية ما. لا تأخذ أدوية أكثر من الموصوفة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هنالك تقارير تشير إلى حدوث تشنجات عند تناول لبيكا أو بعد وقت قصير من التوقف عن تناول لبيكا. إذا عانيت من أي تشنجات، اتصل بطبيبك على الفور.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هناك تقارير عن انخفاض في وظائف المخ (اعتلال دماغي) لدى بعض المرضى الذين يتناولون لبيكا عندما يكون لديهم حالات أخرى. أخبر طبيبك إذا كان لديك تاريخ بأي حالات صحية خطيرة، بما في ذلك أمراض الكبد أو الكلى.</p><p dir="RTL"><strong>الأطفال واليافعين</strong></p><p dir="RTL">لم تثبت السلامة والفعّالية لدى الأطفال واليافعين (الذين تقل أعمارهم عن 18 سنة)، وبالتالي، يتعين عدم استخدام البريجابالين لهذه الفئة العمرية.</p><p dir="RTL"><strong>الأدوية الأخرى ولبيكا</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلاني إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">قد يؤثر لبيكا على بعض الأدوية الأخرى ويتأثر بها (التفاعل). عندما يؤخذ مع بعض الأدوية الأخرى، لبيكا قد يحفز التأثيرات الجانبية التي تمت ملاحظتها مع هذه الأدوية، بما في ذلك الفشل في الجهاز التنفسي والغيبوبة. يمكن أن تزداد درجة الدوخة والنعاس وانخفاض التركيز في حال تناول لبيكا إلى جانب المنتجات الطبية التي تحتوي على:</p><p dir="RTL">أوكسيكودون &ndash; (المستخدمة للتخلص من الألم)</p><p dir="RTL">لورازيبام &ndash; (المستخدمة لعلاج القلق)</p><p dir="RTL">الكحول</p><p dir="RTL">يمكن أخذ لبيكا إلى جانب وسائل منع الحمل التي تؤخذ عن طريق الفم.</p><p dir="RTL"><strong>لبيكا مع الطعام والشراب والكحول</strong></p><p dir="RTL">يمكن تناول لبيكا مع الطعام أو بدونه.</p><p dir="RTL">ينصح بعدم شرب الكحول أثناء تناول لبيكا.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p>يجب عدم تناول لبيكا أثناء فترة الحمل، إلا أذا أخبرك طبيبك خلاف ذلك. يجب على النساء اللواتي لديهن القدرة على الحمل والإنجاب استخدام وسائل منع حمل فعّالة. في حالة الحمل أو الرضاعة الطبيعية أو احتمالية الحمل والتخطيط لإنجاب طفل، اسألي طبيبك أو الصيدلاني للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL"><strong>لقيادة واستخدام الآلات</strong></p><p dir="RTL">قد يسبب لبيكا الشعور بالدوخة والنعاس وانخفاض التركيز. يجب عدم القيادة أو تشغيل الآلات المعقدة أو الانخراط في أنشطة من المحتمل أن تنطوي على مخاطر حتى تعرف ما إذا كان هذا الدواء يؤثر على قدرتك على أداء هذه الأنشطة.</p><p dir="RTL"><strong>أدويكا يحتوي على اللاكتوز مونوهيدرات</strong></p><p dir="RTL">إذا أخبرك طبيبك أنك غير قادر على احتمال بعض أنواع السكر، اتصل بطبيبك قبل تناول هذا المنتج الطبي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائماً كما أخبرك طبيبك تماماً. وإذا لم تكن متأكداً، تحقق من طبيبك أو الصيدلاني.</p><p dir="RTL">سيقوم طبيبك بتحديد الجرعة المناسبة لك. لبيكا مخصص للاستعمال عن طريق الفم فقط.</p><p dir="RTL"><strong>ألم الأعصاب الطرفية والمركزية أو الصرع أو اضطرابات القلق العام:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول عدد الكبسولات وفقاً لتعليمات الطبيب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بشكل عام ستكون الجرعة التي سيتم تحديدها لك ولحالتك ما بين 150 ملجم 600 ملجم يومياً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيخبرك طبيبك أن تتناول لبيكا إما مرتين أو ثلاث مرات يومياً. إذا تقرر مرتين يومياً، تناول لبيكا مرة في الصباح ومرة في المساء، في نفس التوقيت تقريباً كل يوم. إذا تقرر ثلاث مرات يومياً، تناول لبيكا مرة في الصباح ومرة بعد الظهيرة ومرة في المساء، في نفس التوقيت تقريباً كل يوم.</p><p dir="RTL">إذا كان لديك انطباع بأن تأثير لبيكا قوي جداً أو ضعيف جداً، تحدث إلى طبيبك أو الصيدلاني.</p><p dir="RTL">إذا كنت من المرضى كبار السن (أكثر من 65 سنة)، يجب عليك أن تتناول لبيكا بشكل عادي إلا إذا كان لديك مشاكل في الكلى.</p><p>ابتلع الكبسولة بأكملها مع الماء.</p><p dir="RTL">عليك الاستمرار في تناول لبيكا حتى يطلب منك الطبيب التوقف عن ذلك.</p><p dir="RTL"><strong>إذا تناولت جرعة زائد من لبيكا</strong></p><p dir="RTL">اتصل بطبيبك أو توجه إلى أقرب وحدة طوارئ في المستشفى على الفور. خذ علبة كبسولات لبيكا معك. قد تشعر بالنعاس أو التشوش أو التهيج أو عدم الراحة نتيجة لتناولك جرعة زائدة من أدويكا.</p><p dir="RTL"><strong>إذا نسيت تناول لبيكا</strong></p><p dir="RTL">من المهم أن تتناول كبسولات لبيكا المحددة لك بشكل منتظم في نفس الوقت يومياً. إذا نسيت تناول أي جرعة، تناولها حالما تتذكر إلا إذا حان موعد تناول الجرعة التالية. في هذه الحالة، فقط استمر في الجرعة التالية كالمعتاد. لا تتناول جرعة مضاعفة لتعويض الجرعة الفائتة.</p><p dir="RTL"><strong>إذا توقفت عن تناول لبيكا</strong></p><p dir="RTL">لا تتوقف عن تناول لبيكا مالم يخبرك طبيبك بذلك. إذا تم إيقاف علاجك فيجب أن يتم ذلك تدريجياً على مدى 1 أسبوع كحد أدنى.</p><p dir="RTL">بعد التوقف عن العلاج طويل وقصير الأمد باستخدام لبيكا، عليك أن تعرف أنك قد تواجه بعض التأثيرات الجانبية. وتشمل هذه التأثيرات، اضطرابات النوم والصداع والغثيان والشعور بالقلق والإسهال وأعراض مشابهة لأعراض الإنفلونزا والتشنجات، والعصبية والاكتئاب والألم والتعرق والدوخة. قد تحدث هذه الأعراض بصورة شائعة وشديدة أكثر إذا كنت قد تناولت لبيكا لفترة أطول من الزمن.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال في جميع الأدوية، يمكن لهذا الدواء أن يسبب تأثيرات جانبية، على الرغم أنها لا تحصل لكافة الأشخاص.</p><p dir="RTL"><strong>شائعة جداً: قد تؤثر على أكثر من 1 شخص من بين 10 أشخاص:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة، الخمول، الصداع</p><p dir="RTL"><strong>شائعة: قد تؤثر على ما يصل إلى 1 شخص من بين 10 أشخاص:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالانتشاء، والارتباك، التشوش الذهني، وانخفاض في الاهتمام الجنسي والضيق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاضطراب في الانتباه، الارتباك، ضعف الذاكرة، فقدان الذاكرة، الرعاش، صعوبة التحدث، الشعور بالوخز، التنميل، التخدر، الخمول، الأرق، التعب، والشعور بحالة غير طبيعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية، الرؤية المزدوجة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار، مشاكل في التوازن، السقوط</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم، الإمساك، التقيؤ، النفخة، الإسهال، الغثيان، انتفاخ البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبات في الانتصاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الجسم بما في ذلك الأطراف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بحالة سكر، أسلوب مشي غير طبيعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنج العضلات، ألم المفاصل، ألم الظهر، ألم في الأطراف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الحلق</p><p dir="RTL"><strong>غير شائعة: قد تؤثر على ما يصل إلى 1 شخص من بين 100 شخص:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية، خسارة الوزن، انخفاض نسبة السكر في الدم، ارتفاع نسبة السكر في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغير في النظرة إلى الذات، والأرق، والاكتئاب، والتأثيراتة، وتقلب المزاج، وصعوبة إيجاد الكلمات، والهلوسة، وأحلام غير طبيعية، ونوبات الهلع، والوهن، والـعـدوانية، والمزاج المرتفع، الضعف العقلي، وصعوبة التفكير، وزيــادة في الاهتمام الجنسي، ومشاكل في الأداء الجنسي بما في ذلك عدم القدرة على تحقيق الذروة الجنسية، وتأخر القذف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات في البصر، وحركة العين غير العادية، والتغيرات في الرؤية بما في ذلك الرؤية الضيقة، ومضات من الضوء، وحركات متشنجة، وانخفاض ردود الفعل، وزيادة النشاط، والدوخة عند الوقوف، وحساسية الجلد، وفقدان الذوق، والحرقان، والرعاش عند الحركة، وانخفاض الوعي، فقدان الوعي، والإغماء، وزيادة الحساسية للضوضاء، والشعور بالإعياء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف العين، وتورم العين، وآلام في العين، وضعف العيون، والعيون دامعة، وتهيج العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات ضربات القلب، وزيادة معدل ضربات القلب، وانخفاض ضغط الدم، وارتفاع ضغط الدم، والتغيرات في ضربات القلب، وفشل القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحمرار، الاحمرار مع الحرارة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس والأنف الجاف، واحتقان الآنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة افراز اللعاب، والحرقة، والتنميل حول الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التعرق، والطفح الجلدي، والقشعريرة، والحمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الثدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التبول أو ألم اثناء التبول، وسلس البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الضعف، والعطش، وضيق الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتعاش العضلات، تــورم المفاصل، وتصلب العضلات، وآلام بما في ذلك آلام في العضلات، وآلام الرقبة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغييرات في نتائج اختبار الــدم والكبد (زيــادة الكرياتينين فسفوكيناز في الــدم، زيــادة ألانين ترانسفيراز الأميني، وزيـــادة ناقلات الأمين اسبارتاتي، وانخفاض عدد الصفائح الدموية، قلة العدالات، وزيادة الكرياتينين، وانخفاض البوتاسيوم في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الحساسية، تـورم الوجه، الحكة، التحسس، وسيلان الأنف، نزيف الأنف، والسعال، والشخير</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالألم خلال فترة الحيض</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; برودة اليدين والقدمين</p><p dir="RTL"><strong>نادرة: قد تؤثر بما يصل إلى 1 شخص من بين 1,000 شخص:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور غير طبيعي في حاسة الشم ورؤية متأرجحة، إدراك متغير للعمق، السطوع البصري، وفقدان الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتساع حدقة العين، الحول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العرق البارد، والتضيق في الحلق وتورم اللسان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في البلع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركة بطيئة أو قليلة للجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في الكتابة بشكل صحيح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة السوائل في البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السوائل في الرئتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنجات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغييرات في تسجيل التغيرات الكهربائية (ECG) في القلب والتي تتوافق مع اضطرابات إيقاع القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افـرازات بالثدي، ونمو الثدي الغير طبيعي، ونمو الثدي عند الذكور</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقطاع الطمث &quot;الدورة الشهرية&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكلوي، وانخفاض كمية البول، احتباس البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد كريات الدم البيضاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سلوك غير لائق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود الفعل التحسسية &quot;الحساسية&quot; (والتي قد تشمل صعوبة في التنفس، والتهاب العينين (التهاب القرنية) ورد فعل جلدي خطير يتميز بالطفح الجلدي، وظهور البثور، تقشير الجلد والألم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان (اصفرار الجلد والعينين).</p><p dir="RTL"><strong>نادرة جداً: قد تؤثر على ما يصل إلى 1 شخص من بين 10.000 شخص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد (التهاب كبدي)</p><p dir="RTL"><strong>إذا ظهر لديك تورم الوجه أو اللسان أو إذا تحولت بشرتك إلى اللون الأحمر ولاحظت وجود بثور أو تقشير، يجب عليك طلب المشورة الطبية الفورية.</strong></p><p dir="RTL">قد تكون بعض التأثيرات الجانبية أكثر شيوعاً، مثل النعاس، لأن المرضى الذين يعانون من إصابات في النخاع الشوكي قد يتناولون أدوية أخرى لعلاج الألم والتشنج على سبيل المثال، وقد يكون لها تأثيرات جانبية مشابهة لبريجابالين وقد تحدث زيادة في شدة هذه التأثيرات عندما تؤخذ معاً.</p><p dir="RTL">إذا عانيت من أي تأثيرات جانبية، أخبر طبيبك أو الصيدلاني. وهذا يشمل أي تأثيرات جانبية محتملة غير مذكورة في هذه النشرة.</p><p dir="RTL"><strong>الإبلاغ عن التأثيرات الجانبية</strong></p><p dir="RTL">إذا عانيت من أي تأثيرات جانبية، أخبر طبيبك أو الصيدلاني. وهذا يشمل أي تأثيرات جانبية محتملة غير مذكورة في هذه النشرة.</p><p dir="RTL">بالإبلاغ عن التأثيرات الجانبية، يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيداً عن متناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكورة على العلبة الكرتونية أو الزجاجة بعد EXP. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">لا تتخلص من الأدوية عبر مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلاني عن طريقة التخلص من الأدوية التي لم تعد تحتاج إليها. حيث تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعّالة هي بريجابالين. تحتوي كل كبسولة صلبة إما على 75 ملجم أو 150 ملجم أو 30 ملجم بريجابالين.</p><p dir="RTL">المكونات الأخرى: لاكتوز مونوهيدرات، نشا الذرة، تالك، جيلاتين وثنائي أكسيد التيتانيوم (E171). كما تحتوي كبسولات 75 ملجم و300 ملجم على إينديجو كارمين (E132) وإيريثروسين (E171)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>ما هو الشكل الصيدلاني لــ لبيكا وماهي محتويات العبوة</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">كبسولات 75 ملجم</p></td><td style="vertical-align:top"><p dir="RTL">كبسولات صلبة بيضاء وعنابية بحجم حوالي 14 ملم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">كبسولات 150 ملجم</p></td><td style="vertical-align:top"><p dir="RTL">كبسولات صلبة بيضاء بحجم حوالي 18 ملم</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">كبسولات 300 ملجم</p></td><td style="vertical-align:top"><p dir="RTL">كبسولات صلبة بيضاء وعنابية بحجم حوالي 21 ملم</p></td></tr></tbody></table><p>&nbsp;</p><p dir="RTL">كبسولات لبيكا 75 ملجم و150 ملجم و300 ملجم معبأة في عبوة شرائط تحتوي على 30 قرص.</p><p dir="RTL">قد لا يتم تسويق كافة أحجام العبوة.</p><p dir="RTL">يمكنك الإبلاغ عن الآثار الجانبية لـِ:</p><p dir="RTL">- المركز الوطني لليقظة الدوائية:</p><p dir="RTL">- مركز الاتصال في الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">- البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">- الموقع الإلكتروني: https://ade.sfda.gov.sa/</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب رخصة التسويق والشركة المصنعة</strong></p><p dir="RTL">ميديكال فالي إنفست إيه بي،</p><p dir="RTL">برادجاردسفاجن 28</p><p dir="RTL">236 32 هولفيكن</p><p dir="RTL">السويد</p><p dir="RTL"><strong>الشركة المصنعة:</strong></p><p dir="RTL">لابوراتوريوس ليكونسا، إس. إيه.</p><p dir="RTL">أفدا. ميرالكامبو، إن 7، بوليجونو إندستريال ميرالكامبو</p><p dir="RTL">19200 أزوكويكا دي هيناريس (جوادالاجارا)، إسبانيا</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             مايو 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LEPICA 75 mg hard capsules
LEPICA 150 mg hard capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LEPICA 75 mg hard capsules:
Each capsule contains 75 mg of pregabalin.
Excipients: Each capsule contains 8.30 mg of lactose monohydrate

LEPICA 150 mg hard capsules:
Each capsule contains 150 mg of pregabalin.
Excipients: Each capsule contains 16.50 mg of lactose monohydrate For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                LEPICA 75 mg hard capsules:
Hard capsules with white cap and maroon body, with approximate size of 14 mm.

LEPICA 150 mg hard capsules:
Hard capsules with white cap and white body, with approximate size of 18 mm.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Neuropathicpain</u></p><p>LEPICA is indicated for the treatment of peripheral and central neuropathic pain in adults.</p><p>&nbsp;</p><p><em><u>Epilepsy</u></em></p><p>LEPICA is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.</p><p>&nbsp;</p><p><em><u>Generalised Anxiety Disorder</u></em></p><p>LEPICA is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The dose range is 150 to 600 mg per day given in either two or three divided doses.</p><p>&nbsp;</p><p><em><u>Neuropathic pain</u></em></p><p>Pregabalin treatment can be started at a dose of 150 mg per day given as two or three divided doses. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.</p><p>&nbsp;</p><p><em><u>Epilepsy</u></em></p><p>Pregabalin treatment can be started with a dose of 150 mg per day given as two or three divided doses. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. The maximum dose of 600 mg per day may be achieved after an additional week.</p><p>&nbsp;</p><p><em><u>Generalised Anxiety Disorder</u></em></p><p>The dose range is 150 to 600 mg per day given as two or three divided doses. The need for treatment should be reassessed regularly.</p><p>&nbsp;</p><p>Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. Following an additional week the dose may be increased to 450 mg per day. The maximum dose of 600 mg per day may be achieved after an additional week.</p><p>&nbsp;</p><p><em><u>Discontinuation of pregabalin</u></em></p><p>In accordance with current clinical practice, if pregabalin has to be discontinued it is recommended this should be done gradually over a minimum of 1 week independent of the indication (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p><em><u>Patients with renal impairment</u></em></p><p>Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug. As pregabalin clearance is directly proportional to creatinine clearance (see section 5.2), dose reduction in patients with compromised renal function must be individualised according to creatinine clearance (CLcr), as indicated in Table 1 determined using the following formula:</p><p>CL<sub>cr</sub>(ml/min)<img src="data:image/png;base64,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" alt="" width="238" height="57" vspace="0" hspace="0" border="0" style="width:238px;height:57px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" />( x 0.85 for female patients)</p><p>Pregabalin is removed effectively from plasma by haemodialysis (50% of drug in 4 hours). For patients receiving haemodialysis, the pregabalin daily dose should be adjusted based on renal function. In addition to the daily dose, a supplementary dose should be given immediately following every 4 hour haemodialysis treatment (see Table 1).</p><p>&nbsp;</p><p>Table 1. Pregabalin dose adjustment based on renal function</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Creatinine</p><p>clearance (CL<sub>cr</sub>) (mL/min)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>Total pregabalin daily dose *</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Dose regimen</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Starting dose</p><p>(mg/day)</p></td><td style="vertical-align:top"><p>Maximum dose</p><p>(mg/day)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 60</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>600</p></td><td style="vertical-align:top"><p>BID or TID</p></td></tr><tr><td style="vertical-align:top"><p>&ge;30 - &lt;60</p></td><td style="vertical-align:top"><p>75</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>BID or TID</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:467px"><tbody><tr><td style="vertical-align:top; width:164px"><p>&ge;15 - &lt;30</p></td><td style="vertical-align:top; width:97px"><p>25 &ndash; 50</p></td><td style="vertical-align:top; width:106px"><p>150</p></td><td style="vertical-align:top; width:97px"><p>Once Daily or BID</p></td></tr><tr><td style="vertical-align:top; width:164px"><p>&lt; 15</p></td><td style="vertical-align:top; width:97px"><p>25</p></td><td style="vertical-align:top; width:106px"><p>75</p></td><td style="vertical-align:top; width:97px"><p>Once Daily</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:464px"><p>Supplementary dosage following haemodialysis (mg)</p></td></tr><tr><td style="vertical-align:top; width:164px"><p>&nbsp;</p></td><td style="vertical-align:top; width:97px"><p>25</p></td><td style="vertical-align:top; width:106px"><p>100</p></td><td style="vertical-align:top; width:97px"><p>Single dose<sup>+</sup></p></td></tr></tbody></table><p>&nbsp;</p><p>TID = Three divided doses BID = Two divided doses</p><p>* Total daily dose (mg/day) should be divided as indicated by dose regimen to provide mg/dose</p><p>+ Supplementary dose is a single additional dose</p><p>&nbsp;</p><p><em><u>Patients with hepatic impairment</u></em></p><p>No dose adjustment is required for patients with hepatic impairment (see section 5.2).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>The safety and efficacy of LEPICA in children below the age of 12 years and in adolescents (12-17 years of age) have not been established. Currently available data are described in section 4.8, 5.1 and</p><p>5.2 but no recommendation on a posology can be made.</p><p>&nbsp;</p><p><em><u>Elderly (over 65 years of age) population </u></em></p><p>Elderly patients may require a dose reduction of pregabalin due to a decreased renal function (see patients with renal impairment).</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>LEPICA may be taken with or without food. LEPICA is for oral use only.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Diabeticpatients</u></em></p><p>In accordance with current clinical practice, some diabetic patients who gain weight on pregabalin treatment may need to adjust hypoglycaemic medicinal products.</p><p>&nbsp;</p><p><em><u>Hypersensitivity reactions</u></em></p><p>There have been reports in the postmarketing experience of hypersensitivity reactions, including cases of angioedema. Pregabalin should be discontinued immediately if symptoms of angioedema, such as facial, perioral, or upper airway swelling occur.</p><p>&nbsp;</p><p><em><u>Dizziness, somnolence, loss of consciousness, confusion, and mental impairment</u></em></p><p>Pregabalin treatment has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in the elderly population. There have also been post-marketing reports of loss of consciousness, confusion and mental impairment. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medicinal product.</p><p>&nbsp;</p><p><em><u>Vision-related effects</u></em></p><p>In controlled trials, a higher proportion of patients treated with pregabalin reported blurred vision than</p><p>&nbsp;</p><p>did patients treated with placebo which resolved in a majority of cases with continued dosing. In the clinical studies where ophthalmologic testing was conducted, the incidence of visual acuity reduction and visual field changes was greater in pregabalin-treated patients than in placebo-treated patients; the incidence of fundoscopic changes was greater in placebo-treated patients (see section 5.1).</p><p>&nbsp;</p><p>In the post-marketing experience, visual adverse reactions have also been reported, including loss of vision, visual blurring or other changes of visual acuity, many of which were transient.</p><p>Discontinuation of pregabalin may result in resolution or improvement of these visual symptoms.</p><p>&nbsp;</p><p><em><u>Renal failure</u></em></p><p>Cases of renal failure have been reported and in some cases discontinuation of pregabalin did show reversibility of this adverse reaction.</p><p>&nbsp;</p><p><em><u>Withdrawal of concomitant antiepileptic medicinal products</u></em></p><p>There are insufficient data for the withdrawal of concomitant antiepileptic medicinal products, once seizure control with pregabalin in the add-on situation has been reached, in order to reach monotherapy on pregabalin.</p><p>&nbsp;</p><p><em><u>Withdrawal symptoms</u></em></p><p>After discontinuation of short-term and long-term treatment with pregabalin, withdrawal symptoms have been observed in some patients. The following events have been mentioned: insomnia, headache, nausea, anxiety, diarrhoea, flu syndrome, nervousness, depression, pain, convulsion, hyperhidrosis and dizziness, suggestive of physical dependence. The patient should be informed about this at the start of the treatment.</p><p>Convulsions, including status epilepticus and grand mal convulsions, may occur during pregabalin use or shortly after discontinuing pregabalin.</p><p>Concerning discontinuation of long-term treatment of pregabalin, data suggest that the incidence and severity of withdrawal symptoms may be dose-related.</p><p>&nbsp;</p><p><em><u>Congestive heart failure</u></em></p><p>There have been post-marketing reports of congestive heart failure in some patients receiving pregabalin. These reactions are mostly seen in elderly cardiovascular compromised patients during pregabalin treatment for a neuropathic indication. Pregabalin should be used with caution in these patients. Discontinuation of pregabalin may resolve the reaction.</p><p>&nbsp;</p><p><em><u>Treatment of central neuropathic pain due to spinal cord injury</u></em></p><p>In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse reactions in general, central nervous system adverse reactions and especially somnolence was increased. This may be attributed to an additive effect due to concomitant medicinal products (e.g. anti-spasticity agents) needed for this condition. This should be considered when prescribing pregabalin in this condition.</p><p>&nbsp;</p><p><em><u>Suicidal ideation and behaviour</u></em></p><p>Suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents in several indications. A meta-analysis of randomised placebo controlled studies of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk isnot known and the available data do not exclude the possibility of an increased risk for pregabalin.</p><p>&nbsp;</p><p>Therefore patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical&nbsp;</p><p>advice should signs of suicidal ideation or behaviour emerge.</p><p>&nbsp;</p><p><em><u>Reduced lower gastrointestinal tract function</u></em></p><p>There are post marketing reports of events related to reduced lower gastrointestinal tract function (e.g. intestinal obstruction, paralytic ileus, constipation) when pregabalin was co-administered with medications that have the potential to produce constipation, such as opioid analgesics. When pregabalin and opioids will be used in combination, measures to prevent constipation may be considered (especially in female patients and elderly).</p><p>&nbsp;</p><p><em><u>Misuse, abuse potential or dependence</u></em></p><p>Cases of misuse, abuse and dependence have been reported. Caution should be exercised in patients with a history of substance abuse and the patient should be monitored for symptoms of pregabalinmisuse, abuse or dependence (development of tolerance, dose escalation, drug-seeking behaviour have been reported).</p><p>&nbsp;</p><p><em><u>Encephalopathy</u></em></p><p>Cases of encephalopathy have been reported, mostly in patients with underlying conditions that may precipitate encephalopathy.</p><p>&nbsp;</p><p><em><u>Lactose intolerance</u></em></p><p>LEPICA contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (&lt; 2% of a dose recovered in urine as metabolites), does not inhibit drug metabolism <em>in vitro</em>, and is not bound to plasma proteins, it is unlikely to produce, or be subject to, pharmacokinetic interactions.</p><p>&nbsp;</p><p><em><u>In vivo studies and population pharmacokinetic analysis</u></em></p><p>Accordingly, in <em>in vivo </em>studies no clinically relevant pharmacokinetic interactions were observed between pregabalin and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam, oxycodone or ethanol. Population pharmacokinetic analysis indicated that oral antidiabetics, diuretics, insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on pregabalin clearance.</p><p>&nbsp;</p><p><em><u>Oral contraceptives, norethisterone and/or ethinyl oestradiol</u></em></p><p>Co-administration of pregabalin with the oral contraceptives norethisterone and/or ethinyl oestradiol does not influence the steady-state pharmacokinetics of either substance.</p><p>&nbsp;</p><p><em><u>CNS influencing medical products</u></em></p><p>Pregabalin may potentiate the effects of ethanol and lorazepam. In controlled clinical trials, multiple oral doses of pregabalin co-administered with oxycodone, lorazepam, or ethanol did not result in clinically important effects on respiration. In the postmarketing experience, there are reports of respiratory failure and coma in patients taking pregabalin and other CNS depressant medicinal products. Pregabalin appears to be additive in the impairment of cognitive and gross motor function caused by oxycodone.</p><p>&nbsp;</p><p><em><u>Interactions and the elderly</u></em></p><p>No specific pharmacodynamic interaction studies were conducted in elderly volunteers. Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Women of childbearing potential/Contraception in males and females</u></em></p><p>As the potential risk for humans is unknown, effective contraception must be used in women of child bearing potential.</p><p>&nbsp;</p><p><em><u>Pregnancy</u></em></p><p>There are no adequate data from the use of pregabalin in pregnant women.</p><p>&nbsp;</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.</p><p>&nbsp;</p><p>LEPICA should not be used during pregnancy unless clearly necessary (if the benefit to the mother clearly outweighs the potential risk to the foetus).</p><p>&nbsp;</p><p><em><u>Breast-feeding</u></em></p><p>Pregabalin is excreted into human milk (see section 5.2). The effect of pregabalin on newborns/infants is unknown. A decision must be made whether to discontinue breast-feeding or to discontinue pregabalin therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><em><u>Fertility</u></em></p><p>There are no clinical data on the effects of pregabalin on female fertility.</p><p>&nbsp;</p><p>In a clinical trial to assess the effect of pregabalin on sperm motility, healthy male subjects were exposed to pregabalin at a dose of 600 mg/day. After 3 months of treatment, there were no effects on sperm motility.</p><p>&nbsp;</p><p>A fertilty study in female rats has shown adverse reproductive effects. Fertility studies in male rats have shown adverse reproductive and developmental effects. The clinical relevance of these findings is unknown (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>LEPICA may have minor or moderate influence on the ability to drive and use machines. LEPICA may cause dizziness and somnolence and therefore may influence the ability to drive or use machines. Patients are advised not to drive, operate complex machinery or engage in other potentially hazardous activities until it is known whether this medicinal product affects their ability to perform these activities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pregabalin clinical programme involved over 8900 patients who were exposed to pregabalin, of whom over 5600 were in double-blind placebo controlled trials. The most commonly reported adverse reactions were dizziness and somnolence. Adverse reactions were usually mild to moderate in&nbsp;</p><p>intensity. In all controlled studies, the discontinuation rate due to adverse reactions was 12% for patients receiving</p><p>pregabalin and 5% for patients receiving placebo. The most common adverse reactions resulting in discontinuation from pregabalin treatment groups were dizziness and somnolence.</p><p>&nbsp;</p><p>In the table below all adverse reactions, which occurred at an incidence greater than placebo and in</p><p>more than one patient, are listed by class and frequency (very common (&ge;1/10); common (&ge;1/100 to</p><p>&lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>The adverse reactions listed may also be associated with the underlying disease and/or concomitant medicinal products.</p><p>&nbsp;</p><p>In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse reactions in general, CNS adverse reactions and especially somnolence was increased (see section 4.4).</p><p>&nbsp;</p><p>Additional reactions reported from post marketing experience are included in italics in the list below.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse drug reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p><p><!--[if gte vml 1]><v:group id="Group_x0020_21" o:spid="_x0000_s1026"
   style='position:absolute;left:0;text-align:left;margin-left:135.5pt;
   margin-top:5.45pt;width:1.05pt;height:6.1pt;z-index:-16171008;
   mso-wrap-distance-left:0;mso-wrap-distance-right:0' coordsize="13335,77470"
   o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
">
   <v:shape id="Graphic_x0020_22" o:spid="_x0000_s1027" style='position:absolute;
    left:11103;width:1270;height:9525;visibility:visible;mso-wrap-style:square;
    v-text-anchor:top' coordsize="1270,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,9114l,e" filled="f" strokeweight=".1231mm">
    <v:stroke dashstyle="1 1"/>
    <v:path arrowok="t"/>
   </v:shape><v:shape id="Graphic_x0020_23" o:spid="_x0000_s1028" style='position:absolute;
    left:11103;top:9114;width:1270;height:9525;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="1270,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,9105l,e" filled="f" strokeweight=".1231mm">
    <v:stroke dashstyle="1 1"/>
    <v:path arrowok="t"/>
   </v:shape><v:shape id="Graphic_x0020_24" o:spid="_x0000_s1029" style='position:absolute;
    left:11103;top:18232;width:1270;height:9525;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="1270,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,9105l,e" filled="f" strokeweight=".1231mm">
    <v:stroke dashstyle="1 1"/>
    <v:path arrowok="t"/>
   </v:shape><v:shape id="Graphic_x0020_25" o:spid="_x0000_s1030" style='position:absolute;
    left:11103;top:27341;width:1270;height:9525;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="1270,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,9114l,e" filled="f" strokeweight=".1231mm">
    <v:stroke dashstyle="1 1"/>
    <v:path arrowok="t"/>
   </v:shape><v:shape id="Graphic_x0020_26" o:spid="_x0000_s1031" style='position:absolute;
    left:11103;top:36457;width:1270;height:9525;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="1270,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,9105l,e" filled="f" strokeweight=".1231mm">
    <v:stroke dashstyle="1 1"/>
    <v:path arrowok="t"/>
   </v:shape><v:shape id="Graphic_x0020_27" o:spid="_x0000_s1032" style='position:absolute;
    left:11103;top:45576;width:1270;height:9525;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="1270,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,9108l,e" filled="f" strokeweight=".1231mm">
    <v:stroke dashstyle="1 1"/>
    <v:path arrowok="t"/>
   </v:shape><v:shape id="Graphic_x0020_28" o:spid="_x0000_s1033" style='position:absolute;
    left:11103;top:54684;width:1270;height:9525;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="1270,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,9103l,e" filled="f" strokeweight=".1231mm">
    <v:stroke dashstyle="1 1"/>
    <v:path arrowok="t"/>
   </v:shape><v:shape id="Graphic_x0020_29" o:spid="_x0000_s1034" style='position:absolute;
    left:11103;top:63800;width:1270;height:9525;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="1270,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,9105l,e" filled="f" strokeweight=".1231mm">
    <v:stroke dashstyle="1 1"/>
    <v:path arrowok="t"/>
   </v:shape><v:shape id="Graphic_x0020_30" o:spid="_x0000_s1035" style='position:absolute;
    left:11103;top:72919;width:1270;height:5080;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="1270,5080" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,4546l,em,4546l,e" filled="f" strokeweight=".1231mm">
    <v:path arrowok="t"/>
   </v:shape><v:shape id="Graphic_x0020_31" o:spid="_x0000_s1036" style='position:absolute;
    left:6665;top:40648;width:1270;height:9525;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="1270,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQADEmIexAAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/basJA
FEXfBf9hOIJvOlHBSnQUL5T2QShePuCQOSbBzJk4M01iv75TKPi42ZfFXm06U4mGnC8tK5iMExDE
mdUl5wqul/fRAoQPyBory6TgSR42635vham2LZ+oOYdcxBH2KSooQqhTKX1WkEE/tjVx9G7WGQxR
ulxqh20cN5WcJslcGiw5EgqsaV9Qdj9/mwg5zH8+DvvjY/dc3N+aaSsdH7+UGg667RJEoC68wv/t
T61gNoG/L/EHyPUvAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAAMSYh7EAAAA2wAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" path="m,9202l,e" filled="f" strokeweight=".1234mm">
    <v:stroke dashstyle="1 1"/>
    <v:path arrowok="t"/>
   </v:shape><v:shape id="Graphic_x0020_32" o:spid="_x0000_s1037" style='position:absolute;
    left:6665;top:49855;width:1270;height:9525;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="1270,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,9194l,e" filled="f" strokeweight=".1234mm">
    <v:stroke dashstyle="1 1"/>
    <v:path arrowok="t"/>
   </v:shape><v:shape id="Graphic_x0020_33" o:spid="_x0000_s1038" style='position:absolute;
    left:6665;top:59058;width:1270;height:9525;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="1270,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCcjFnyxAAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/basJA
FEXfBf9hOIJvOlHBSnQUL0j7IBQvH3DIHJNg5kw6M01iv75TKPi42ZfFXm06U4mGnC8tK5iMExDE
mdUl5wpu1+NoAcIHZI2VZVLwJA+bdb+3wlTbls/UXEIu4gj7FBUUIdSplD4ryKAf25o4enfrDIYo
XS61wzaOm0pOk2QuDZYcCQXWtC8oe1y+TYQc5j/vh/3pa/dcPN6aaSsdnz6VGg667RJEoC68wv/t
D61gNoO/L/EHyPUvAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAJyMWfLEAAAA2wAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" path="m,9200l,e" filled="f" strokeweight=".1234mm">
    <v:stroke dashstyle="1 1"/>
    <v:path arrowok="t"/>
   </v:shape><v:shape id="Graphic_x0020_34" o:spid="_x0000_s1039" style='position:absolute;
    left:6665;top:68270;width:1270;height:9525;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="1270,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQATZcGGwwAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/fasIw
FMbvB3uHcAbeaTo3VKpRpiLzQhDdHuDQHNtic1KTrK0+vRGEXX58f358s0VnKtGQ86VlBe+DBARx
ZnXJuYLfn01/AsIHZI2VZVJwJQ+L+evLDFNtWz5Qcwy5iCPsU1RQhFCnUvqsIIN+YGvi6J2sMxii
dLnUDts4bio5TJKRNFhyJBRY06qg7Hz8MxGyHt2+16vdZXmdnMfNsJWOd3ulem/d1xREoC78h5/t
rVbw8QmPL/EHyPkdAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAE2XBhsMAAADbAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" path="m,9194l,e" filled="f" strokeweight=".1234mm">
    <v:stroke dashstyle="1 1"/>
    <v:path arrowok="t"/>
   </v:shape><v:shape id="Graphic_x0020_35" o:spid="_x0000_s1040" style='position:absolute;
    left:2221;top:40648;width:1270;height:9525;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="1270,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,9202l,e" filled="f" strokeweight=".1234mm">
    <v:stroke dashstyle="1 1"/>
    <v:path arrowok="t"/>
   </v:shape><v:shape id="Graphic_x0020_36" o:spid="_x0000_s1041" style='position:absolute;
    left:2221;top:49855;width:1270;height:9525;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="1270,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,9194l,e" filled="f" strokeweight=".1234mm">
    <v:stroke dashstyle="1 1"/>
    <v:path arrowok="t"/>
   </v:shape><v:shape id="Graphic_x0020_37" o:spid="_x0000_s1042" style='position:absolute;
    left:2221;top:59056;width:1270;height:9525;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="1270,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,9201l,e" filled="f" strokeweight=".1234mm">
    <v:stroke dashstyle="1 1"/>
    <v:path arrowok="t"/>
   </v:shape><v:shape id="Graphic_x0020_38" o:spid="_x0000_s1043" style='position:absolute;
    left:2221;top:68270;width:1270;height:9525;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' coordsize="1270,9525" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,9194l,e" filled="f" strokeweight=".1234mm">
    <v:stroke dashstyle="1 1"/>
    <v:path arrowok="t"/>
   </v:shape></v:group><![endif]--><img width="3" height="10" src="file:///C:/Users/MAALAS~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nasopharyngitis <strong>Blood and lymphatic system disorders </strong>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neutropenia <strong>Immune system disorders</strong></p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Hypersensitivity</em></p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Angioedema, allergic reaction</em></p><p><strong>Metabolism and nutrition disorders</strong></p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Appetite increased</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anorexia, hypoglycaemia</p><p><strong>Psychiatric disorders</strong></p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Euphoric mood, confusion, irritability, disorientation, insomnia, libido decreased</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hallucination, panic attack, restlessness, agitation, depression,</p><p>depressed mood, elevated mood, <em>aggression</em>, mood swings, depersonalisation, word finding difficulty, abnormal dreams, libido increased, anorgasmia, apathy</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disinhibition</p><p><strong>Nervous system disorders</strong></p><p>Very Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, somnolence, headache</p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ataxia, coordination abnormal, tremor, dysarthria, amnesia, memory impairment, disturbance in attention, paraesthesia, hypoaesthesia, sedation, balance disorder, lethargy</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Syncope, stupor, myoclonus, <em>loss of consciousness</em>, psychomotor</p><p>hyperactivity, dyskinesia, dizziness postural, intention tremor, nystagmus, cognitive disorder, <em>mental impairment</em>, speech disorder, hyporeflexia, hyperaesthesia, burning sensation, ageusia, <em>malaise</em></p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Convulsions</em>, parosmia, hypokinesia, dysgraphia</p><p><strong>Eye disorders</strong></p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vision blurred, diplopia</p></td></tr></tbody></table><table border="1" cellspacing="1" cellpadding="1" style="width:869px"><tbody><tr><td style="width:866px"><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peripheral vision loss, visual disturbance, eye swelling, visual field defect, visual acuity reduced, eye pain, asthenopia,&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; photopsia, dry eye, lacrimation increased, eye irritation</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Vision loss</em>, <em>keratitis</em>, oscillopsia, altered visual depth perception, mydriasis, strabismus, visual brightness</p><p><strong>Ear and labyrinth disorders</strong></p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vertigo</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperacusis</p><p><strong>Cardiac disorders</strong></p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tachycardia, atrioventricular block first degree, sinus bradycardia,&nbsp;<em>congestive heart failure</em></p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>QT prolongation</em>, sinus tachycardia, sinus arrhythmia</p><p><strong>Vascular disorders</strong></p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension, hypertension, hot flushes, flushing, peripheral coldness</p><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyspnoea, epistaxis, cough, nasal congestion, rhinitis, snoring,nasal dryness</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Pulmonary oedema</em>, throat tightness</p><p><strong>Gastrointestinal disorders</strong></p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting, <em>nausea</em>, constipation, <em>diarrhoea</em>, flatulence, abdominal distension, dry mouth</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastrooesophageal reflux disease, salivary hypersecretion, hypoaesthesia oral</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ascites, pancreatitis, <em>swollen tongue</em>, dysphagia</p><p><strong>Hepatobiliary disorders</strong></p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated liver enzymes*</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jaundice</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatic failure, hepatitis</p><p><strong>Skin and subcutaneous tissue disorders</strong></p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash papular, urticaria, hyperhidrosis, <em>pruritus</em></p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Stevens Johnson syndrome</em>, cold sweat</p><p><strong>Musculoskeletal and connective tissue disorders</strong></p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle cramp, arthralgia, back pain, pain in limb, cervical spasm</p><p>Uncommon&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Joint swelling,&nbsp; myalgia, muscle twitching, neck pain, muscle stiffness</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rhabdomyolysis</p><p><strong>Renal and urinary disorders</strong></p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary incontinence, dysuria</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal failure, oliguria, <em>urinary retention</em></p><p><strong>Reproductive system and breast disorders</strong></p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Erectile dysfunction</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sexual dysfunction, ejaculation delayed, dysmenorrhoea, breast pain</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amenorrhoea, breast discharge, breast enlargement,&nbsp;<em>gynaecomastia</em></p><p><strong>General disorders and administration site conditions</strong></p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oedema peripheral, oedema, gait abnormal, fall, feeling drunk, feeling abnormal, fatigue</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Generalised oedema, <em>face oedema</em>, chest tightness, pain, pyrexia, thirst, chills, asthenia</p><p><strong>Investigations</strong></p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight increased</p><p>Uncommon&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp; &nbsp; Blood creatine phosphokinase increased, blood glucose increased, platelet count decreased, blood creatinine increased,&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;blood potassium decreased, weight decreased</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;White blood cell count decreased</p></td></tr></tbody></table><p>*Alanine aminotransferase increased (ALT) and aspartate aminotransferase increased (AST).</p><p>&nbsp;</p><p>After discontinuation of short-term and long-term treatment with pregabalin withdrawal symptoms have been observed in some patients. The following reactions have been mentioned: insomnia, headache, nausea, anxiety, diarrhoea, flu syndrome, convulsions, nervousness, depression, pain<strong>, </strong>hyperhidrosis and dizziness, suggestive of physical dependence. The patient should be informed about this at the start of the treatment.</p><p>&nbsp;</p><p>Concerning discontinuation of long-term treatment of pregabalin, data suggest that the incidence and severity of withdrawal symptoms may be dose-related.</p><p>&nbsp;</p><p><em><u>Paediatricpopulation</u></em></p><p>The pregabalin safety profile observed in three paediatric studies in patients with partial seizures with or without secondary generalization (12-week efficacy and safety study in patients with partial onset seizures, n=295; pharmacokinetic and tolerability study, n=65; and 1 year open label follow on safety study, n=54) was similar to that observed in the adult studies of patients with epilepsy. The most common adverse events observed in the 12-week study with pregabalin treatment were somnolence, pyrexia, upper respiratory tract infection, increased appetite, weight increased, and nasopharyngitis (see sections 4.2, 5.1 and 5.2).</p><p>&nbsp;</p><p><em><u>Reporting of suspected adverse reactions</u></em></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p>&nbsp;</p><p><u>To reports any side effect(s):</u></p><p><strong>Saudi Arabia:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>https://ade.sfda.gov.sa/</u></p><p><strong>Other GCC States:</strong></p><p>-&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the post-marketing experience, the most commonly reported adverse reactions observed when pregabalin was taken in overdose included somnolence, confusional state, agitation, and restlessness. Seizures were also reported.</p><p>&nbsp;</p><p>In rare occasions, cases of coma have been reported.</p><p>&nbsp;</p><p>Treatment of pregabalin overdose should include general supportive measures and may include haemodialysis if necessary (see section 4.2 Table 1).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antiepileptics, other antiepileptics ATC code: N03AX16</p><p>&nbsp;</p><p>The active substance, pregabalin, is a gamma-aminobutyric acid analogue ((S)-3-(aminomethyl)- 5methylhexanoic acid).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Mechanism of action </u></p><p><!--[if gte vml 1]><v:group id="Group_x0020_43" o:spid="_x0000_s1026"
 style='position:absolute;left:0;text-align:left;margin-left:252.45pt;
 margin-top:.5pt;width:57.05pt;height:39.15pt;z-index:15733760;
 mso-wrap-distance-left:0;mso-wrap-distance-right:0;
 mso-position-horizontal-relative:page;mso-width-relative:margin;
 mso-height-relative:margin' coordsize="7249,4976" o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
 <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
  o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Image_x0020_44" o:spid="_x0000_s1027" type="#_x0000_t75"
  style='position:absolute;width:3111;height:1739;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/MAALAS~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
 </v:shape><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
  path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Textbox_x0020_45" o:spid="_x0000_s1028" type="#_x0000_t202"
  style='position:absolute;left:4137;top:3185;width:3112;height:1791;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAW/S4yxAAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvBf/D8oTe6sbSikZXEVEQCqUxHjw+s89kMfs2za4a/71bKHgcZuYbZrbobC2u1HrjWMFwkIAg
Lpw2XCrY55u3MQgfkDXWjknBnTws5r2XGaba3Tij6y6UIkLYp6igCqFJpfRFRRb9wDXE0Tu51mKI
si2lbvEW4baW70kykhYNx4UKG1pVVJx3F6tgeeBsbX6/jz/ZKTN5Pkn4a3RW6rXfLacgAnXhGf5v
b7WCj0/4+xJ/gJw/AAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhABb9LjLEAAAA2wAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" filled="f" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-top:1.25pt;margin-right:0in;margin-bottom:
     0in;margin-left:5.3pt;margin-bottom:.0001pt'><sub><span style='letter-spacing:
     -.25pt'>2</span></sub><span style='letter-spacing:-.25pt'>-</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="79" height="54" src="file:///C:/Users/MAALAS~1/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />Pregabalin binds to an auxiliary subunit ( central nervous system.</p><p>&nbsp;</p><p><u>Clinical Efficacy and safety </u></p><p>&nbsp;</p><p>&nbsp;</p><p>protein) of voltage-gated calcium channels in the</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Neuropathic pain</em></p><p>Efficacy has been shown in trials in diabetic neuropathy, post herpetic neuralgia and spinal cord injury. Efficacy has not been studied in other models of neuropathic pain.</p><p>&nbsp;</p><p>Pregabalin has been studied in 10 controlled clinical trials of up to 13 weeks with twice a day dosing (BID) and up to 8 weeks with three times a day (TID) dosing. Overall, the safety and efficacy profiles for BID and TID dosing regimens were similar.</p><p>&nbsp;</p><p>In clinical trials up to 12 weeks for both peripheral and central neuropathic pain, a reduction in pain was seen by Week 1 and was maintained throughout the treatment period.</p><p>&nbsp;</p><p>In controlled clinical trials in peripheral neuropathic pain 35% of the pregabalin treated patients and 18% of the patients on placebo had a 50% improvement in pain score. For patients not experiencing somnolence, such an improvement was observed in 33% of patients treated with pregabalin and 18% of patients on placebo. For patients who experienced somnolence the responder rates were 48% on pregabalin and 16% on placebo.</p><p>&nbsp;</p><p>In the controlled clinical trial in central neuropathic pain 22% of the pregabalin treated patients and 7% of the patients on placebo had a 50% improvement in pain score.</p><p>&nbsp;</p><p><em>Epilepsy</em></p><p>Adjunctive Treatment&nbsp;</p><p>Pregabalin has been studied in 3 controlled clinical trials of 12 week duration with either BID or TID dosing. Overall, the safety and efficacy profiles for BID and TID dosing regimens were similar.</p><p>&nbsp;</p><p>A reduction in seizure frequency was observed by Week 1.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The efficacy and safety of pregabalin as adjunctive treatment for epilepsy in paediatric patients below the age of 12 and adolescents has not been established. The adverse events observed in apharmacokinetic and tolerability study that enrolled patients from 3 months to 16 years of age (n=65) with partial onset seizures were similar to those observed in adults. Results of a 12-week</p><p>placebo-controlled study of 295 paediatric patients aged 4 to 16 years performed to evaluate the efficacy and safety of pregabalin as adjunctive therapy for the treatment of partial onset seizures and a 1 year open label safety study in 54 paediatric patients from 3 months to 16 years of age with epilepsy indicate that the adverse events of pyrexia and upper respiratory infections were observed more frequently than in adult studies of patients with epilepsy (see sections 4.2, 4.8 and 5.2).</p><p>&nbsp;</p><p>In the 12-week placebo-controlled study, paediatric patients were assigned to pregabalin</p><p>2.5 mg/kg/day (maximum, 150 mg/day), pregabalin 10 mg/kg/day (maximum, 600 mg/day), or placebo. The percentage of subjects with at least a 50% reduction in partial onset seizures as compared to baseline was 40.6% of subjects treated with pregabalin 10 mg/kg/day (p=0.0068 versus placebo), 29.1% of subjects treated with pregabalin 2.5 mg/kg/day (p=0.2600 versus placebo) and 22.6% of those receiving placebo.</p><p>&nbsp;</p><p>Monotherapy (newly diagnosed patients)</p><p>Pregabalin has been studied in 1 controlled clinical trial of 56 week duration with twice a day dosing (BID). Pregabalin did not achieve non-inferiority to lamotrigine based on the 6-month seizure freedom endpoint. Pregabalin and lamotrigine were similarly safe and well tolerated.</p><p>&nbsp;</p><p><em><u>Generalised Anxiety Disorder</u></em></p><p>Pregabalin has been studied in 6 controlled trials of 4-6 week duration, an elderly study of 8 week duration and a long-term relapse prevention study with a double blind relapse prevention phase of 6 months duration.</p><p>&nbsp;</p><p>Relief of the symptoms of GAD as reflected by the Hamilton Anxiety Rating Scale (HAM-A) was observed by Week 1.</p><p>&nbsp;</p><p>In controlled clinical trials (4-8 week duration) 52% of the pregabalin treated patients and 38% of the patients on placebo had at least a 50% improvement in HAM-A total score from baseline to endpoint.</p><p>&nbsp;</p><p>In controlled trials, a higher proportion of patients treated with pregabalin reported blurred vision than did patients treated with placebo which resolved in a majority of cases with continued dosing.</p><p>Ophthamologic testing (including visual acuity testing, formal visual field testing and dilated funduscopic examination) was conducted in over 3600 patients within controlled clinical trials. In these patients, visual acuity was reduced in 6.5% of patients treated with pregabalin, and 4.8% of placebo-treated patients. Visual field changes were detected in 12.4% of pregabalin-treated, and 11.7% of placebo-treated patients. Funduscopic changes were observed in 1.7% of pregabalin-treated and 2.1% of placebo-treated patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregabalin steady-state pharmacokinetics are similar in healthy volunteers, patients with epilepsy receiving anti-epileptic drugs and patients with chronic pain.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>Pregabalin is rapidly absorbed when administered in the fasted state, with peak plasma concentrations occurring within 1 hour following both single and multiple dose administration. Pregabalin oral bioavailability is estimated to be &ge; 90% and is independent of dose. Following repeated administration, steady state is achieved within 24 to 48 hours. The rate of pregabalin absorption is decreased when given with food resulting in a decrease in C<sub>max</sub> by approximately 25-30% and a delay in t<sub>max</sub> to approximately 2.5 hours. However, administration of pregabalin with food has no clinically significant effect on the extent of pregabalin absorption.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Distribution</u></p><p>In preclinical studies, pregabalin has been shown to cross the blood brain barrier in mice, rats, and monkeys. Pregabalin has been shown to cross the placenta in rats and is present in the milk of lactating rats. In humans, the apparent volume of distribution of pregabalin following oral administration is approximately 0.56 l/kg. Pregabalin is not bound to plasma proteins.</p><p>&nbsp;</p><p><u>Biotransformation </u></p><p>Pregabalin undergoes negligible metabolism in humans. Following a dose of radiolabelled pregabalin, approximately 98% of the radioactivity recovered in the urine was unchanged pregabalin. The Nmethylated derivative of pregabalin, the major metabolite of pregabalin found in urine, accounted for 0.9% of the dose. In preclinical studies, there was no indication of racemisation of pregabalin Senantiomer to the R-enantiomer.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Pregabalin is eliminated from the systemic circulation primarily by renal excretion as unchanged drug. Pregabalin mean elimination half-life is 6.3 hours. Pregabalin plasma clearance and renal clearance are directly proportional to creatinine clearance (see section 5.2 Renal impairment).</p><p>&nbsp;</p><p>Dose adjustment in patients with reduced renal function or undergoing haemodialysis is necessary (see section 4.2 Table 1).</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>Pregabalin pharmacokinetics are linear over the recommended daily dose range. Inter-subject pharmacokinetic variability for pregabalin is low (&lt; 20%). Multiple dose pharmacokinetics are predictable from single-dose data. Therefore, there is no need for routine monitoring of plasma concentrations of pregabalin.</p><p>&nbsp;</p><p><u>Gender</u></p><p>Clinical trials indicate that gender does not have a clinically significant influence on the plasma concentrations of pregabalin.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>Pregabalin clearance is directly proportional to creatinine clearance. In addition, pregabalin is effectively removed from plasma by haemodialysis (following a 4 hour haemodialysis treatment plasma pregabalin concentrations are reduced by approximately 50%). Because renal elimination is the major elimination pathway, dose reduction in patients with renal impairment and dose&nbsp;</p><p>supplementation following haemodialysis is necessary (see section 4.2 Table 1).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>No specific pharmacokinetic studies were carried out in patients with impaired liver function. Since pregabalin does not undergo significant metabolism and is excreted predominantly as unchanged drug in the urine, impaired liver function would not be expected to significantly alter pregabalin plasma concentrations.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Pregabalin pharmacokinetics were evaluated in paediatric patients with epilepsy (age groups: 1 to</p><p>23 months, 2 to 6 years, 7 to 11 years and 12 to 16 years) at dose levels of 2.5, 5, 10 and 15 mg/kg/day in a pharmacokinetic and tolerability study.</p><p>&nbsp;</p><p>After oral administration of pregabalin in paediatric patients in the fasted state, in general, time to reach peak plasma concentration was similar across the entire age group and occurred 0.5 hours to 2 hours postdose.</p><p>&nbsp;</p><p>Pregabalin Cmax and AUC parameters increased in a linear manner with increasing dose within each age group. The AUC was lower by 30% in paediatric patients below a weight of 30 kg due to an increased body weight adjusted clearance of 43% for these patients in comparison to patients weighing</p><p>&ge;30 kg.</p><p>&nbsp;</p><p>Pregabalin terminal half-life averaged about 3 to 4 hours in paediatric patients up to 6 years of age, and 4 to 6 hours in those 7 years of age and older.Population pharmacokinetic analysis showed that creatinine clearance was a significant covariate of pregabalin oral clearance, body weight was a significant covariate of pregabalin apparent oral volume of distribution, and these relationships were similar in paediatric and adult patients.</p><p>&nbsp;</p><p>Pregabalin pharmacokinetics in patients younger than 3 months old have not been studied (see sections 4.2, 4.8 and 5.1).</p><p>&nbsp;</p><p><u>Elderly (over 65 years of age) </u></p><p>Pregabalin clearance tends to decrease with increasing age. This decrease in pregabalin oral clearance is consistent with decreases in creatinine clearance associated with increasing age. Reduction of pregabalin dose may be required in patients who have age related compromised renal function (see section 4.2 Table 1).</p><p>&nbsp;</p><p><u>Breast-feedingmothers</u></p><p>The pharmacokinetics of 150 mg pregabalin given every 12 hours (300 mg daily dose) was evaluated in 10 lactating women who were at least 12 weeks postpartum. Lactation had little to no influence on pregabalin pharmacokinetics. Pregabalin was excreted into breast milk with average steady-state concentrations approximately 76% of those in maternal plasma. The estimated infant dose from breast milk (assuming mean milk consumption of 150 ml/kg/day) of women receiving 300 mg/day or the maximum dose of 600 mg/day would be 0.31 or 0.62 mg/kg/day, respectively. These estimated doses are approximately 7% of the total daily maternal dose on a mg/kg basis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In conventional safety pharmacology studies in animals, pregabalin was well-tolerated at clinically relevant doses. In repeated dose toxicity studies in rats and monkeys CNS effects were observed,</p><p>&nbsp;</p><p>including hypoactivity, hyperactivity and ataxia. An increased incidence of retinal atrophy commonly observed in aged albino rats was seen after long-term exposure to pregabalin at exposures &ge; 5 times the mean human exposure at the maximum recommended clinical dose.</p><p>&nbsp;</p><p>Pregabalin was not teratogenic in mice, rats or rabbits. Foetal toxicity in rats and rabbits occurred only at exposures sufficiently above human exposure. In prenatal/postnatal toxicity studies, pregabalin induced offspring developmental toxicity in rats at exposures &gt; 2 times the maximum recommended human exposure.</p><p>&nbsp;</p><p>Adverse effects on fertility in male and female rats were only observed at exposures sufficiently in excess of therapeutic exposure. Adverse effects on male reproductive organs and sperm parameters were reversible and occurred only at exposures sufficiently in excess of therapeutic exposure or were associated with spontaneous degenerative processes in male reproductive organs in the rat. Therefore the effects were considered of little or no clinical relevance.</p><p>&nbsp;</p><p>Pregabalin is not genotoxic based on results of a battery of <em>in vitro </em>and <em>in vivo </em>tests.</p><p>&nbsp;</p><p>Two-year carcinogenicity studies with pregabalin were conducted in rats and mice. No tumours were observed in rats at exposures up to 24 times the mean human exposure at the maximum recommended clinical dose of 600 mg/day. In mice, no increased incidence of tumours was found at exposures similar to the mean human exposure, but an increased incidence of haemangiosarcoma was observed at higher exposures. The non-genotoxic mechanism of pregabalin-induced tumour formation in mice involves platelet changes and associated endothelial cell proliferation. These platelet changes were not present in rats or in humans based on short term and limited long term clinical data. There is no evidence to suggest an associated risk to humans.</p><p>&nbsp;</p><p>In juvenile rats the types of toxicity do not differ qualitatively from those observed in adult rats. However, juvenile rats are more sensitive. At therapeutic exposures, there was evidence of CNS clinical signs of hyperactivity and bruxism and some changes in growth (transient body weight gain suppression). Effects on the oestrus cycle were observed at 5-fold the human therapeutic exposure.Reduced acoustic startle response was observed in juvenile rats 1-2 weeks after exposure at</p><p>&gt; 2 times the human therapeutic exposure. Nine weeks after exposure, this effect was no longer observable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>LEPICA 75 mg hard capsules:</u></p><p>&nbsp;</p><p><em>Capsule content: </em></p><p>Lactose monohidrate</p><p>Maize starch</p><p>Talc</p><p>&nbsp;</p><p><em>Capsule shell:</em></p><p>Gelatin</p><p>Titanium Dioxide (E171)</p><p>Indigo Carmine (E132)</p><p>Erythrosine (E127)</p><p><u>LEPICA 150 mg hard capsules:</u></p><p>&nbsp;</p><p><em>Capsule content:</em></p><p>Lactose monohidrate</p><p>Maize starch</p><p>Talc</p><p>&nbsp;</p><p><em>Capsule shell:</em></p><p>Gelatin</p><p>Titanium Dioxide (E171)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium/Aluminium-Polyamide-PVC or Aluminium/PVC-PVDC blisters:</p><p>&nbsp;</p><p>LEPICA 75 mg contains 14, 30, 56, 70, 100, 112 hard capsules or 100 x 1 hard capsules in perforated unit dose blisters</p><p><!--[if gte vml 1]><v:shape
 id="Graphic_x0020_46" o:spid="_x0000_s1026" style='position:absolute;left:0;
 text-align:left;margin-left:109.4pt;margin-top:11.5pt;width:2.8pt;height:.55pt;
 z-index:15734272;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;v-text-anchor:top' coordsize="35560,6985"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" path="m35052,l,,,6858r35052,l35052,xe" fillcolor="black" stroked="f">
 <v:path arrowok="t"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="4" height="1" src="file:///C:/Users/MAALAS~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />LEPICA 150 mg contains 14, 30, 56, 70, 100, 112 hard capsules or 100 x 1 hard capsules in perforated unit dose blisters</p><p>&nbsp;</p><p>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Medical Valley Invest AB, Bradgardsvagen 28
236 32 Hollviken Sweden

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                20 May 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>